Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis

By sjmartinez • July 16, 2024

Volkmann ER, Denton CP, Kolb M, Wijsenbeek-Lourens MS, Emson C, Hudson K, Amatucci AJ, Distler O, Allanore Y, Khanna D. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis. Eur Respir Rev. 2024 Jun 12;33(172):240015. doi: 10.1183/16000617.0015-2024. PMID: 39009409.

Tags: Publications, Rheumatology

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]

Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase in Aeromonas spp

von Bredow B, Trejo M, Ward KW, Trieu KP, Santellan CA, Garner OB, Yang S, Chandrasekaran S. Discrepancy between reference phenotypic and genotypic detection of cphA metallo-β-lactamase[...]

Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial

Budoff MJ, Verghese D, Kinninger A, Lakshmanan S. Plaque, P-Values, and Presentation Bias: Four Limitations of the EKSTROM Trial. Eur Heart J Cardiovasc Imaging. 2026[...]